Evidence map›Paper›PMID 35801532›Full record

ArticleBone & joint research2022

Analysis of combined deficiency of interleukin-1 and -6 versus single deficiencies in TNF-mediated arthritis and systemic bone loss.

Silvia Hayer, Birgit Niederreiter, Marlene Kalkgruber, Konrad Wanic, Julia Maißner, Josef S Smolen, Daniel Aletaha, Stephan Blüml, Kurt Redlich

Open access · goldAbstract read
In one paragraph

Article in Bone & joint research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Developing anFrontiers in immunology · 2025
    Article
  3. Mechanistic Exploration ofPharmaceuticals (Basel, Switzerland) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Silvia HayerDepartment of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-1334-5668
Birgit NiederreiterDepartment of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-6032-3499
Marlene KalkgruberDepartment of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-2703-1264
Konrad WanicDepartment of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-2995-7781
Julia MaißnerDepartment of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0001-9390-1075
Josef S SmolenDepartment of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-4302-8877
Daniel AletahaDepartment of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-2108-0030
Stephan BlümlDepartment of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0002-2758-4400
Kurt RedlichDepartment of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria.ORCID 0000-0003-3693-0958
Medical University of Vienna · ATKlinik Hietzing · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsInsufficient treatment response in rheumatoid arthritis (RA) patients requires novel treatment strategies to halt disease progression. The potential benefit of combination of cytokine-inhibitors in RA is still unclear and needs further investigation. To explore the impact of combined deficiency of two major cytokines, namely interleukin (IL)-1 and IL-6, in this study double deficient mice for IL-1αβ and IL-6 were investigated in different tumour necrosis factor (TNF)-driven inflammatory bone disorders, namely peripheral arthritis and sacroiliitis, as well as systemic bone loss.

methodsDisease course, histopathological features of arthritis, and micro-CT (µCT) bone analysis of local and systemic bone loss were assessed in 15-week-old

resultsCombined deficiency of IL-1/IL-6 markedly ameliorated TNF-mediated arthritis and bilateral sacroiliitis, but without additive benefits compared to single IL-1 deficiency. This finding confirms the important role of IL-1 and the marginal role of IL-6 in TNF-driven pathways of local joint damage, but questions the efficacy of potential combinatorial therapies of IL-1 and IL-6 in treatment of RA. In contrast, combined deficiency of IL-1/IL-6 led to an additive protective effect on TNF-driven systemic bone loss compared to single IL-1 and IL-6 deficiency. This finding clearly indicates a common contribution of both IL-1 and IL-6 in TNF-driven systemic bone loss, and points to a discrepancy of cytokine dependency in local and systemic TNF-driven mechanisms of inflammatory arthritis.

conclusionCombinatorial treatments in RA might provide different benefits to inflammatory local arthritis and systemic comorbidities. Cite this article:

Indexed as

arthritisCytokinecytokinesExperimental arthritisIL-6inflammatory arthritisInflammatory joint damageInflammatory systemic bone lossinterleukinjoint damageMicro-CTosteopeniasacroiliitistumour necrosis factor

Identifiers

PMID35801532
PMCPMC9350695
OpenAlexW4284895796

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.